Navigation Links
Bobbi Drais Promoted to Vice President, Regulatory Affairs for HEALTHPOINT, Ltd.
Date:5/7/2009

FORT WORTH, Texas, May 7 /PRNewswire/ -- HEALTHPOINT, Ltd., a DFB Pharmaceuticals, Inc. company, has announced the promotion of Bobbi Drais to Vice President of Regulatory Affairs. Ms. Drais, with 15 years of regulatory experience, was most recently Senior Director of Regulatory Affairs for the company.

Since joining Healthpoint in 2003, Ms. Drais has achieved landmark regulatory success for DFB and Healthpoint. Ms. Drais initially established the regulatory department for Healthpoint. She and her team secured new drug approval (NDA) and marketing authorization approval (MAA) for ATRALIN(TM) (tretinoin) Gel in the US and Europe, respectively, the first Healthpoint proprietary product to achieve such approval. Ms. Drais was also instrumental in gaining regulatory approval of Collagenase SANTYL(R) Ointment in Canada.

"With Bobbi at the helm of all regulatory functions, I have great confidence that Healthpoint can seamlessly continue along its trajectory of success," said Travis E. Baugh, President of Healthpoint. "We're fortunate to have such a seasoned professional in this role as we navigate the regulatory waters. We count on her tremendously."

Prior to joining the DFB family of companies, Ms. Drais was Regulatory Affairs Manager for Galderma Laboratories, LP, Carrington Laboratories, Inc. and Smith & Nephew, Inc.

Ms. Drais graduated from Messiah College in Grantham, Pa., with a Bachelor of Science degree in biology. She also earned a Master of Science degree in microbiology from the University of South Florida in Tampa, Fla. Ms. Drais maintains memberships in the Regulatory Affairs Professional Society and the Drug Information Association, and she holds a Regulatory Affairs Certification (RAC).

Since 1992, HEALTHPOINT has been dedicated to innovative technologies for the prevention and treatment of acute, chronic and burn-related wounds. The company is presently focused on the research and development of novel biologics and pharmaceuticals intended to improve clinical and quality of life outcomes. Currently marketed products include: Collagenase SANTYL(R) Ointment, OASIS(R) Wound Matrix, HYDROFERA BLUE(R) Bacteriostatic Wound Dressings, and SURGICEPT(R) Waterless Surgical Hand Antiseptic. HEALTHPOINT is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from THE WOUND INSTITUTE(R). To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com(R). HEALTHPOINT is a DFB Pharmaceuticals, Inc. affiliate company, and is based in Fort Worth, Texas. For more information, visit the HEALTHPOINT website at www.healthpoint.com.


'/>"/>
SOURCE HEALTHPOINT, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bobbi Brown Cosmetics Creates Limited-Edition Lip Palette in Partnership with The Heart Truths Red Dress Collection 2008 Fashion Show
2. Bobbi Brown Cosmetics Creates Limited-Edition Red Lip Palette in Partnership With The Heart Truths 2008 Red Dress Collection
3. CWs 7th Heaven Actress Mackenzie Rosman to Visit Birmingham Area High School to Honor Cystic Fibrosis Foundation Fundraising
4. Bone Marrow Registry to Launch Groundbreaking Fundraising Technology to Overcome Madoff Crisis
5. Khanna Institute Supports Oaks Christian School's Annual Fundraiser
6. Maryland Mystery Author Organizes Fundraising Ride for Rare Neurological Disorder
7. West Coast Bank Sponsors Reach the Beach Cycling Fundraiser to Support the American Lung Association
8. Country Star Phil Vassar to Perform at Transplantation Fundraiser
9. American Airlines Applauded for Its Fundraising to Support Susan G. Komen for the Cure(R), Promise Grant to The University of Texas M. D. Anderson Cancer Center
10. Safeway Slated to Top $100 Million Contribution Mark to Easter Seals and Families Living with Autism and Other Disabilities with Launch of Fundraising Campaign
11. Safeway Slated to Top $100 Million Contribution Mark to Easter Seals and Families Living with Autism and Other Disabilities with Launch of Fundraising Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
(Date:1/17/2017)... ... 17, 2017 , ... Surgeons from New York’s fastest growing ... on the latest breakthroughs in the prevention, diagnosis and treatment of the most ... eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD and Managing ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading ... a Principal in its IT Advisory Services practice . Rossi is the third ... market demand for strategic IT guidance grows, and the practice continues to expand.     , ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/16/2017)... , ... January 17, 2017 , ... Recently, patients and ... Southwest Michigan, joined other volunteers and organizations in support of the annual Binder Park ... and families dressed up in colorful costumes of all designs coming out to enjoy ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), ... - Global Forecast to 2021" report to their offering. ... The global active ... 2021 from USD 157.95 Billion in 2016, growing at a CAGR ...
(Date:1/17/2017)... 17, 2017 Immune Pharmaceuticals (NASDAQ: ... today that it will hold a Satellite Symposium on February ... (ISAL) XVI in Munich, Germany . ... Efficacy of Immunotherapy for the maintenance of remission in ... 20 th , 2017 from 12:45 – 13:45 CET ...
(Date:1/17/2017)... PARSIPPANY, N.J. , Jan. 17, 2017 Interpace ... that provides clinically useful molecular diagnostic tests and pathology ... it has received a letter dated January 13, 2017 ... it has regained compliance with the requirement of the ... price of $1.00 per share. The letter ...
Breaking Medicine Technology: